A citation-based method for searching scientific literature

Jae Min Cho, Hye Won Jang, Hwanju Cheon, Yeon Taek Jeong, Do-Hoon Kim, Yu-Mi Lim, Song-Hyen Choi, Eun-Kyoung Yang, Chang-Yell Shin, Moon Ho Son, Soon Hoe Kim, Heung-Jae Kim, Myung-Shik Lee. Diabetes Res Clin Pract 2011
Times Cited: 40







List of co-cited articles
302 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.
J Andrew Pospisilik, Jennifer Martin, Timothy Doty, Jan A Ehses, Nathalie Pamir, Francis C Lynn, Shalea Piteau, Hans-Ulrich Demuth, Christopher H S McIntosh, Raymond A Pederson. Diabetes 2003
273
32

DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes.
Mi-Kyung Kim, Yu Na Chae, Ha Dong Kim, Eun Kyoung Yang, Eun Jung Cho, Song-hyen Choi, Ye-Hwang Cheong, Hae-Sun Kim, Heung Jae Kim, Yeong Woo Jo,[...]. Life Sci 2012
44
27

Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.
James Mu, John Woods, Yun-Ping Zhou, Ranabir Sinha Roy, Zhihua Li, Emanuel Zycband, Yue Feng, Lan Zhu, Cai Li, Andrew D Howard,[...]. Diabetes 2006
353
25

Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Heung Jae Kim, Woo Young Kwak, Jong Pil Min, Jae Young Lee, Tae Hyun Yoon, Ha Dong Kim, Chang Yell Shin, Mi Kyung Kim, Song Hyen Choi, Hae Sun Kim,[...]. Bioorg Med Chem Lett 2011
34
29


Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes.
James Mu, Aleksandr Petrov, George J Eiermann, John Woods, Yun-Ping Zhou, Zhihua Li, Emanuel Zycband, Yue Feng, Lan Zhu, Ranabir Sinha Roy,[...]. Eur J Pharmacol 2009
95
20


Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor.
Lei Tian, Jie Gao, Jianqiang Hao, Yu Zhang, Huimin Yi, Timothy D O'Brien, Robert Sorenson, Jian Luo, Zhiguang Guo. Endocrinology 2010
87
20


Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers.
Namyi Gu, Min Kyu Park, Tae-Eun Kim, Mi Young Bahng, Kyoung Soo Lim, Sang-Heon Cho, Seo Hyun Yoon, Joo-Youn Cho, In-Jin Jang, Kyung-Sang Yu. Drug Des Devel Ther 2014
28
28


A randomized, double-blind, placebo-controlled, phase II clinical trial to investigate the efficacy and safety of oral DA-1229 in patients with type 2 diabetes mellitus who have inadequate glycaemic control with diet and exercise.
Chang Hee Jung, Cheol-Young Park, Kyu-Joeng Ahn, Nan-Hee Kim, Hak-Chul Jang, Moon-Kyu Lee, Joong-Yeol Park, Choon-Hee Chung, Kyung-Wan Min, Yeon-Ah Sung,[...]. Diabetes Metab Res Rev 2015
25
28


The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice.
Jacob Jelsing, Niels Vrang, Søren B van Witteloostuijn, Michael Mark, Thomas Klein. J Endocrinol 2012
37
16

Evaluation of the pharmacokinetics, food effect, pharmacodynamics, and tolerability of DA-1229, a dipeptidyl peptidase IV inhibitor, in healthy volunteers: first-in-human study.
Tae-Eun Kim, Kyoung Soo Lim, Min Kyu Park, Seo-Hyun Yoon, Joo-Youn Cho, Sang-Goo Shin, In-Jin Jang, Kyung-Sang Yu. Clin Ther 2012
17
35

Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance.
Stacey L Conarello, Zhihua Li, John Ronan, Ranabir Sinha Roy, Lan Zhu, Guoqiang Jiang, Franklin Liu, John Woods, Emanuel Zycband, David E Moller,[...]. Proc Natl Acad Sci U S A 2003
260
12

The physiology of glucagon-like peptide 1.
Jens Juul Holst. Physiol Rev 2007
12

The biology of incretin hormones.
Daniel J Drucker. Cell Metab 2006
12



Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome.
Daniela Lamers, Susanne Famulla, Nina Wronkowitz, Sonja Hartwig, Stefan Lehr, D Margriet Ouwens, Kristin Eckardt, Jean M Kaufman, Mikael Ryden, Stefan Müller,[...]. Diabetes 2011
378
12

Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial.
S L Ellis, E G Moser, J K Snell-Bergeon, A S Rodionova, R M Hazenfield, S K Garg. Diabet Med 2011
89
12


Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice.
Jun Shirakawa, Hideki Fujii, Kei Ohnuma, Koichiro Sato, Yuzuru Ito, Mitsuyo Kaji, Eri Sakamoto, Megumi Koganei, Hajime Sasaki, Yoji Nagashima,[...]. Diabetes 2011
182
12

Dipeptidyl peptidase 4 inhibitor sitagliptin maintains β-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study.
Yunjuan Zhao, Lin Yang, Yufei Xiang, Lingjiao Liu, Gan Huang, Zhaofeng Long, Xia Li, R David Leslie, Xiangbing Wang, Zhiguang Zhou. J Clin Endocrinol Metab 2014
74
12

Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.
Anne-Marie Lambeir, Christine Durinx, Simon Scharpé, Ingrid De Meester. Crit Rev Clin Lab Sci 2003
619
10

Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice.
Y Takeda, Y Fujita, J Honjo, T Yanagimachi, H Sakagami, Y Takiyama, Y Makino, A Abiko, T J Kieffer, M Haneda. Diabetologia 2012
93
10


Effect of sitagliptin plus metformin on β-cell function, islet integrity and islet gene expression in Zucker diabetic fatty rats.
Seung Jin Han, Sung-E Choi, Yup Kang, Jong Gab Jung, Sang-A Yi, Hae Jin Kim, Kwan Woo Lee, Dae Jung Kim. Diabetes Res Clin Pract 2011
20
20

Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice.
A D Dobrian, Q Ma, J W Lindsay, K A Leone, K Ma, J Coben, E V Galkina, J L Nadler. Am J Physiol Endocrinol Metab 2011
108
10

Exendin-4 modulates diabetes onset in nonobese diabetic mice.
Irene Hadjiyanni, Laurie L Baggio, Philippe Poussier, Daniel J Drucker. Endocrinology 2008
79
10

Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells.
Nicole A Sherry, Wei Chen, Jake A Kushner, Mariela Glandt, Qizhi Tang, Sue Tsai, Pere Santamaria, Jeffrey A Bluestone, Anne-Marie B Brillantes, Kevan C Herold. Endocrinology 2007
138
10

Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes.
Alexandra E Butler, Juliette Janson, Susan Bonner-Weir, Robert Ritzel, Robert A Rizza, Peter C Butler. Diabetes 2003
10

Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
10

Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice.
Wilma L Suarez-Pinzon, Robert F Power, Yanhua Yan, Clive Wasserfall, Mark Atkinson, Alex Rabinovitch. Diabetes 2008
132
10



Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat).
Liliana Ferreira, Edite Teixeira-de-Lemos, Filipa Pinto, Belmiro Parada, Cristina Mega, Helena Vala, Rui Pinto, Patrícia Garrido, José Sereno, Rosa Fernandes,[...]. Mediators Inflamm 2010
125
10

Sitagliptin exerts an antinflammatory action.
Antoine Makdissi, Husam Ghanim, Mehul Vora, Kelly Green, Sanaa Abuaysheh, Ajay Chaudhuri, Sandeep Dhindsa, Paresh Dandona. J Clin Endocrinol Metab 2012
174
10


DPP4 in Diabetes.
Diana Röhrborn, Nina Wronkowitz, Juergen Eckel. Front Immunol 2015
178
10


Combining MK626, a novel DPP-4 inhibitor, and low-dose monoclonal CD3 antibody for stable remission of new-onset diabetes in mice.
Lei Ding, Conny A Gysemans, Geert Stangé, Yves Heremans, Yixing Yuchi, Tatiana Takiishi, Hannelie Korf, Marie Chintinne, Richard D Carr, Harry Heimberg,[...]. PLoS One 2014
15
26


Beneficial Effects of Evogliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, on Adiposity with Increased Ppargc1a in White Adipose Tissue in Obese Mice.
Yu-Na Chae, Tae-Hyoung Kim, Mi-Kyung Kim, Chang-Yell Shin, Il-Hoon Jung, Yong Sung Sohn, Moon-Ho Son. PLoS One 2015
18
22

The DPP-4 inhibitor linagliptin restores β-cell function and survival in human isolated islets through GLP-1 stabilization.
Payal Shah, Amin Ardestani, Gitanjali Dharmadhikari, Svenja Laue, Desiree M Schumann, Julie Kerr-Conte, Francois Pattou, Thomas Klein, Kathrin Maedler. J Clin Endocrinol Metab 2013
65
10

Efficacy and safety of adding evogliptin versus sitagliptin for metformin-treated patients with type 2 diabetes: A 24-week randomized, controlled trial with open label extension.
Sang-Mo Hong, Cheol-Young Park, Dong-Min Hwang, Kyung Ah Han, Chang Beom Lee, Choon Hee Chung, Kun-Ho Yoon, Ji-Oh Mok, Kyong Soo Park, Sung-Woo Park. Diabetes Obes Metab 2017
16
25





Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.